Kelun-Biotech Announces Phase II Results for KH607 in Major Depressive Disorder

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has reported topline results from its Phase II clinical trial evaluating KH607, a novel candidate for the treatment of Major Depressive Disorder (MDD). The study compared the efficacy and safety of the investigational drug against vortioxetine, a serotonin modulator and stimulator currently used to treat depression, according to company disclosures.

Clinical Trial Design and Primary Endpoints

The randomized, double-blind, active-controlled study aimed to assess the therapeutic potential of KH607 in patients diagnosed with MDD. The primary endpoint of the trial was the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at day 22. The MADRS is a standard 10-item diagnostic questionnaire used by clinicians to measure the severity of depressive episodes in patients, as defined by the National Institutes of Health.

Researchers measured efficacy by comparing the reduction in MADRS scores between the group receiving KH607 and the group receiving vortioxetine. The study design followed standard regulatory requirements for psychiatric drug development, focusing on both the statistical significance of symptom reduction and the safety profile of the experimental compound compared to the established control medication.

Understanding KH607 and Vortioxetine

KH607 is part of Kelun-Biotech’s internal R&D pipeline, which focuses on developing targeted therapies for chronic and severe diseases. By selecting vortioxetine as the active comparator, the trial sought to demonstrate how KH607 performs against a widely prescribed antidepressant. Vortioxetine, originally developed by Lundbeck and Takeda, functions by inhibiting serotonin reuptake and modulating various serotonin receptor subtypes, according to FDA prescribing information.

The use of an active comparator rather than a placebo is a rigorous standard in depression research, as it provides data on whether a new drug offers clinical advantages—such as improved efficacy or a better side-effect profile—over existing treatments.

Safety and Regulatory Context

Safety monitoring throughout the trial included the tracking of adverse events, vital signs, and laboratory assessments. Clinical trials for depression medications typically require close observation of patient responses to ensure that the reduction in depressive symptoms is not offset by significant side effects, such as gastrointestinal distress or sexual dysfunction, which are common with many traditional antidepressants.

Kelun-Biotech’s development of KH607 represents the company’s broader strategy to expand its portfolio beyond oncology into central nervous system (CNS) disorders. Following the completion of this Phase II study, the company will determine the next steps for the clinical development program, which may include larger Phase III trials if the data supports further investment and regulatory filing.

Key Details

• Primary Endpoint: Change in MADRS total score at day 22.
• Comparator: Vortioxetine (active control).
• Focus Area: Major Depressive Disorder (MDD).
• Developer: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

The results of the Phase II trial are expected to guide the company’s future interactions with global regulatory bodies, including the National Medical Products Administration (NMPA) in China and potentially the U.S. Food and Drug Administration (FDA), depending on the company’s regional commercialization strategy.